ArticleCardiovascular diabetology2025
Improving 10-year cardiovascular risk prediction in patients with type 2 diabetes with metabolomics.
Article in Cardiovascular diabetology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Stacking Ensemble Learning for Diagnosing Acute Myocardial Infarction in Mice Using Plasma Raman Spectroscopy and Mass Spectrometry.Journal of cardiovascular translational research · 2026Article
- Metabolomics-Defined Subtypes of Prediabetes and Risk of Cardiovascular-Kidney-Metabolic Outcomes.Diabetes · 2026Article
- Associations of Life's Essential 8 cardiovascular health score with prevalent microvascular complications stratified by sex and menopausal status in Chinese adults with type 2 diabetes: a cross-sectional study.BMJ open diabetes research & care · 2026Article
- A cardiometabolic risk phenotype index integrating insulin resistance, systemic inflammation, and psychological burden for mortality risk stratification in metabolic dysfunction-associated steatotic liver disease: an exploratory longitudinal analysis of a nationally representative cohort.Lipids in health and disease · 2026Article
- Risk Factors for Cardiovascular Disease: Epidemiology, Screening, Prevention, and Therapeutic Interventions.MedComm · 2026Review
- Sarcopenia and Its Associated Metabolic Profile Predict Incident Heart Failure: A Prospective Cohort Study of 267 335 Adults in the UK Biobank.Journal of the American Heart Association · 2026Article
- Risk prediction for individual patients and the pitfalls of selecting an optimal prediction model: do not judge a model by its c-statistic.European journal of epidemiology · 2026Article
- Study on the construction of a predictive model for delayed encephalopathy after acute carbon monoxide poisoning.BMC neurology · 2026Article
- DNA2 acts as a brake on β cell insulin hypersecretion and diet-induced metabolic dysfunction.Frontiers in cell and developmental biology · 2026Article
- Metabolomic profiling refines cardiovascular risk stratification beyond SCORE2-diabetes in patients with concurrent type 2 diabetes and pulmonary dysfunction.Frontiers in endocrinology · 2026Article
- Identification of a plasma proteomic signature associated with sudden cardiac death risk in the UK biobank.Frontiers in cardiovascular medicine · 2026Article
- Socio-ecological factors of health literacy and physical activity among middle-aged and older Chinese adults.Frontiers in public health · 2026Article
- Association between mental health and MASLD molecular insights through metabolomics.Communications medicine · 2025Article
- Improved sex-specific cardiovascular risk prediction with multi-omics data in people with type 2 diabetes.Cardiovascular diabetology · 2025Article
- Article
- Nutrigenomics meets multi-omics: integrating genetic, metabolic, and microbiome data for personalized nutrition strategies.Genes & nutrition · 2025Review
- Metabolomic Biomarkers Are Independently Associated With Secondary Adverse Cardiovascular Events in Patients With Coronary Artery Disease.Journal of the American Heart Association · 2025Article
- Circulating inflammation-related proteome improves cardiovascular risk prediction. Results from two large European cohort studies.European journal of epidemiology · 2025Article
- Advances in Metabolomics: A Comprehensive Review of Type 2 Diabetes and Cardiovascular Disease Interactions.International journal of molecular sciences · 2025Review
- The NMR-measured omega-6/omega-3 fatty acid ratio improves cardiovascular risk prediction.Frontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundExisting cardiovascular risk prediction models still have room for improvement in patients with type 2 diabetes who represent a high-risk population. This study evaluated whether adding metabolomic biomarkers could enhance the 10-year prediction of major adverse cardiovascular events (MACE) in these patients.
methodsData from 10,257 to 1,039 patients with type 2 diabetes from the UK Biobank (UKB) and the German ESTHER cohort, respectively, were used for model derivation, internal and external validation. A total of 249 metabolites were measured with nuclear magnetic resonance (NMR) spectroscopy. Sex-specific LASSO regression with bootstrapping identified significant metabolites. The enhanced model's predictive performance was evaluated using Harrell's C-index.
resultsSeven metabolomic biomarkers were selected by LASSO regression for enhanced MACE risk prediction (three for both sexes, three male- and one female-specific metabolite(s)). Especially albumin and the omega-3-fatty-acids-to-total-fatty-acids-percentage among males and lactate among females improved the C-index. In internal validation with 30% of the UKB, adding the selected metabolites to the SCORE2-Diabetes model increased the C-index statistically significantly (P = 0.037) from 0.660 to 0.678 in the total sample. In external validation with ESTHER, the C-index increase was higher (+ 0.043) and remained statistically significant (P = 0.011).
conclusionsIncorporating seven metabolomic biomarkers in the SCORE2-Diabetes model enhanced its ability to predict MACE in patients with type 2 diabetes. Given the latest cost reduction and standardization efforts, NMR metabolomics has the potential for translation into the clinical routine.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.